⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 22, 2025Open Access

Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

John D. Powderly Martina Imbimbo Antoîne Italiano Patricia Martín-Romano Meredith McKean Teresa Macarulla Eduardo Castañón Álvarez Benedito A. Carneiro Raymond Mager Vicky Barnhart Steven Eck Elina Murtomaki Arsène‐Bienvenu Loembé Yun He Zachary A. Cooper Eric Tu Chunling Fan Agnes Boyer Chamard Carine Paturel Paula G. Fraenkel Antoine Hollebecque

View Full Paper

Ask AI

Bookmark

Share

Key Points

The treatment shows promising results in advanced solid tumors, indicating a potential new avenue for therapy.
Combining anti-cd39 mab with durvalumab improves patient responses compared to monotherapy.
The observational study involved a diverse cohort of patients with advanced solid tumors, aiming to assess treatment efficacy.
These findings highlight the importance of exploring combination therapies for better outcomes in cancer management.

Implication

Assessment of anti-cd39 mab alone or with durvalumab on patient outcomes in advanced solid tumors, suggesting potential benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Powderly et al. (2025) studied this question.

synapsesocial.com/papers/68d4725631b076d99fa6b12e https://doi.org/10.1158/2767-9764.30177712

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
2Table S4 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
3Table S5 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
4Table S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
5Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025